Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Media Dermato-Venereologica Indonesiana Cermin Dunia Kedokteran
Andrianus, Kenny
Unknown Affiliation
Health Professions

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
PITYRIASIS LICHENOIDES PASCA VAKSINASI mRNA COVID-19 Laurensia, Riani; Nadia Yusharyahya, Shannaz; Legiawati, Lili; Astriningrum, Rinadewi; Rihatmadja, Rahadi; Andrianus, Kenny
Media Dermato-Venereologica Indonesiana Vol 53 No 1 (2026): Media Dermato Venereologica Indonesiana
Publisher : Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33820/mdvi.v53i1.514

Abstract

   Pendahuluan: Pityriasis lichenoides (PL) merupakan spektrum kelainan kulit yang tumpang tindih secara klinis maupun histopatologis dengan dua bentuk utama yaitu pityriasis lichenoides et varioliformis acuta (PLEVA) dan pityriasis lichenoides chronica (PLC). Sekitar 20% PL terjadi pada anak-anak dan dewasa muda. Beberapa publikasi ilmiah melaporkan PL pascavaksinasi coronavirus disease (COVID-19). Kasus: Seorang laki-laki, 64 tahun didiagnosis PL, 4 hari pascavaksinasi COVID-19 booster pertama Pfizer® sejak 14 bulan lalu. Pemeriksaan dermoskopi ditemukan dotted vessels, yellowish-orange structureless area, vesicles with red background. Pemeriksaan laboratorium didapatkan peningkatan D-dimer 490 mG/L dan IgE 730 IU/ml. Pemeriksaan histopatologi kulit sesuai PLEVA, ditemukannya eosinofil dipertimbangkan sebagai hipersensitivitas vaksin. Perbaikan klinis signifikan tercapai dengan terapi metilprednisolon setara prednison 0.5 mg/kgBB dan doksisiklin selama 2 minggu. Diskusi: : Patogenesis PL disebabkan oleh peningkatan kompleks imun, deposit IgM, dan C3 pada vaskular taut dermo-epidermal, serta kumpulan sel sitotoksik pada dermis dan epidermis yang berkorelasi dengan hipersensitivitas tipe lambat terhadap bahan vaksin. Pemeriksaan histopatologi membantu menegakkan diagnosis. Terapi kortikosteroid dan doksisiklin memberikan respon terapi dan luaran klinis yang baik pada P. Simpulan: Kasus PL pascavaksinasi Pfizer® COVID-19, perbaikan klinis dengan terapi kortikosteroid dan doksisiklin, serta pentingnya mengawasi efek samping pascavaksinasi, pemeriksaan klinis dan evaluasi histopatologi penting dalam penegakan diagnosis.
Efektivitas dan Keamanan Dupilumab pada Remaja dengan Dermatitis Atopik yang Tidak Terkendali: Tinjauan Sistematis: Tinjauan Sistematis Andrianus, Kenny; Agustin, Triana; Hapsari, Windy Atika
Cermin Dunia Kedokteran Vol 53 No 07 (2026): Juli 2026
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v53i07.2072

Abstract

Introduction: Up to 24.6% of young adults worldwide suffer from atopic dermatitis. Dupilumab was originally intended for adults with uncontrolled moderate to severe atopic dermatitis. As of March 2019, it has been approved by the US Food and Drug Administration (FDA) for use in adolescents aged 12 to 17. This article aims to evaluate the efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis compared to standard therapy. Methods: A literature search was conducted in June 2020 across Cochrane, EBSCO, and PubMed using specific medical subject heading (MeSH) terms. Inclusion and exclusion criteria were applied. Only relevant articles were selected and appraised using the Center for Evidence-based Medicine (CEBM) tools. Results: Two articles were selected: 1 RCT and 1 cohort study, with 251 and 40 subjects, respectively. Both studies showed statistically significant reductions across all parameters evaluated with Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Pruritus Numerical Rating Scales. The effectiveness of dupilumab is positively correlated with dosage, frequency, and treatment duration. In both studies, the 4 mg per kg body weight group compared to the 2 mg per kg body weight group, and the every 2 weeks’ protocol compared to the every 4 weeks’ protocol showed better effectiveness. The most common side effects include conjunctivitis, skin infections, and local reactions due to injections. Conclusion: Dupilumab is effective for treating uncontrolled atopic dermatitis in adolescents. The IGA, EASI, and pruritus NRS parameters showed significant reductions. Side effects associated with dupilumab are minimal and well-tolerated.
Co-Authors Astriningrum, Rinadewi Laurensia, Riani Lili Legiawati Nadia Yusharyahya, Shannaz Rahadi Rihatmadja Triana Agustin Windy Atika Hapsari, Windy Atika